Abstracts tagged "Inflammation"

Abstract Number: 1810 • ACR Convergence 2024
Modulation of Type I Interferon Signaling by Anifrolumab Alters the Spatial Immune Landscape in Cutaneous Lupus Erythematosus
Ksenia Anufrieva¹, Rochelle Castillo², Ce Gao², Jessica Liu², Neda Shahriari², Kimberly Hashemi², Dustin Taylor³, Rachael Rowley², Elizabeth Rainone², Avery LaChance², Rachel Gate⁴, ilya Korsunsky², Ruth Ann Vleugels⁵ and Kevin Wei⁶, ¹BWH, Cambridge, MA, ²Brigham and Women's Hospital, Boston, MA, ³Vanderbilt University Medical Center, Nashville, TN, ⁴10x Genomics, Pleasanton, CA, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: Reliable and effective treatments for refractory cutaneous lupus erythematosus (CLE) remained elusive until the arrival of anifrolumab, a monoclonal antibody targeting the type I…
Abstract Number: 2032 • ACR Convergence 2024
A Systematic Review of Treatment Strategies in VEXAS Syndrome
Aviraag Vijaya Prakash¹, Jose Garcia², Anurag Goel³, Vinit Gilvaz⁴ and Raveena Midha⁵, ¹Saint Vincent Hospital, Department of Internal Medicine, Worcester, MA, ²Brown University, East Greenwich, RI, ³The Warren Alpert Medical School of Brown University, Providence, RI, ⁴The Warren Alpert Medical School of Brown University, East Providence, RI, ⁵Kent Hospital/Brown University, Warwick, RI
Background/Purpose: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, first described in 2020, is an autoinflammatory condition characterized by somatic mutations in the UBA1 gene.…
Abstract Number: 2557 • ACR Convergence 2024
The Relation of Colchicine to Knee/hip Replacement Among People with Gout in a Population-based Cohort Study
Zhiqiang Wang¹, Sarah Tilley², Christine Peloquin², Eva Petrow³, Margaret Clancy² and Tuhina Neogi², ¹Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, Guangdong, China (People's Republic), ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Boston Medical Center, Boston, MA
Background/Purpose: Colchicine, an anti-inflammatory drug commonly used in gout, has been associated with a lower incidence of total knee/hip replacement compared to placebo among participants…
Abstract Number: 0023 • ACR Convergence 2024
Adenosine and Guanosine-based Oligonucleotide Attenuates Catabolic Phenotypes in Chondrocytes and Slows Progression of Surgically Induced Osteoarthritis
Yoonhee Kim¹, Jin Han² and Seungwoo Han³, ¹Kyungpook National University School of Medicine, Buk-gu, Daegu, Republic of Korea, ²Kyungpook National University, Buk-gu, Daegu, Republic of Korea, ³Kyungpook national university hospital, Daegu, South Korea
Background/Purpose: Adenosine is a potent endogenous modulator of inflammation; however, its clinical application is limited due to its extremely short half-life in blood. In this…
Abstract Number: 0230 • ACR Convergence 2024
Spine and Sacroiliac Joint Involvement in Newly Diagnosed Patients with Inflammatory Bowel Disease – Clinical and MRI Findings from a Population-Based Cohort Study
Nora Vladimirova¹, Jakob Møller², Mohamed Attauabi², Gorm Madsen³, Lene Terslev⁴, Charlotte Wiell⁵, Viktoria Fana⁶, Sanja Bay Hansen³, Hartwig Siebner³, Jakob Seidelin², Flemming Bentsen³, Kasper Gosvig⁷, Johan Burisch³ and Mikkel Ostergaard⁸, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Righospitalet, Copenhagen, Denmark, ²Herlev and Gentofte Hospital, copenhagen, Denmark, ³Hvidovre Hospital, copenhagen, Denmark, ⁴Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, ⁵Rigshospitalet-Glostrup, Copenhagen, Denmark, ⁶Rigshospitalet-Glostrup, Glostrup, Denmark, ⁷Department of Radiology, Copenhagen University Hospital Herlev-Gentofte, Herlev, Denmark, ⁸Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: In patients with inflammatory bowel disease (IBD), coexistence of spondyloarthritis (SpA), the most common extraintestinal manifestation, is associated with poor outcomes and impaired quality…
Abstract Number: 0562 • ACR Convergence 2024
Serum Interleukin IL-40 as a Potential Biomarker Associated with Pro-inflammatory Activity in Inflammatory Bowel Diseases and Spondyloarthritis: A Preliminary Study
Lucia Ondrejčáková¹, Adéla Navrátilová², Monika Gregová³, Kristýna Bubová⁴, Tomáš Grega⁵, Ladislav Šenolt⁶, Karel Pavelka⁷ and Lucie Andrés Cerezo⁸, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, ²1st Faculty of Medicine, Charles University and Institute of Rheumatology in Prague, Hlavní mesto Praha, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, ⁴Institute of Rheumatology and Charles University, Prague, Czech Republic, ⁵3Department of Internal Medicine, First Faculty of Medicine, Charles University, Military University Hospital, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Interleukin 40 (IL-40) is a novel cytokine with a proposed role in the pathogenesis of inflammatory diseases. Inflammatory bowel diseases (IBD)-associated with spondyloarthritis (SpA)…
Abstract Number: 0846 • ACR Convergence 2024
Three Novel Metabolomic Signatures of Inflammation for Female Gout Risk: A Prospective Cohort Study over 26 Years
Sharan Rai¹, Hyon K. Choi², Chio Yokose¹ and Natalie McCormick¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Lexington, MA
Background/Purpose: Only 20% of those with hyperuricemia develop clinically evident gout, suggesting that other, likely inflammatory, factors influence NLRP3 inflammasome activation and progression to gout.…
Abstract Number: 0957 • ACR Convergence 2024
Increased Collagen Deposition and Altered Immune Cell Profiles Are Present in Early and Late Stage Systemic Sclerosis with Gastrointestinal Involvement
Laura Much¹, Elena Pachera², Andrea Laimbacher¹, Henriette Didriksen³, Lars Aabakken⁴, Knut Ea Lundin⁴, Lumeng Li¹, Astrid Hofman¹, Pietro Bearzi⁵, Sophie Wagner⁶, Michael Scharl⁷, Øyvind Molberg⁸, Håvard Fretheim⁹, Oliver Distler¹⁰ and Anna-Maria Hoffmann-Vold⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Oslo University Hospital, Moss, Norway, ⁴Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁶University of Zurich, Schlieren, Switzerland, ⁷Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁹Oslo University Hospital, Oslo, Norway, ¹⁰Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Gastrointestinal tract (GIT) involvement is highly prevalent among patients with systemic sclerosis (SSc) and is associated with high morbidity and mortality. However, treatment options…
Abstract Number: 1577 • ACR Convergence 2024
Elevated Neutrophil Extracellular Traps in Systemic Sclerosis-associated Vasculopathy and Suppression by a Synthetic Prostacyclin Analog
Neda Kortam¹, Wenying Liang¹, Claire Shiple¹, Suiyuan Huang¹, Rosemary Gedert¹, James St. Clair¹, Cyrus Sarosh², Caroline Foster¹, Eliza Pei-Suen Tsou¹, John Varga¹, Jason Knight¹, Dinesh Khanna¹ and Ramadan Ali¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI
Background/Purpose: Neutrophils and neutrophil extracellular traps (NETs) contribute to the vascular complications of multiple diseases, but their role in systemic sclerosis (SSc) is understudied. We…
Abstract Number: 1830 • ACR Convergence 2024
Single-cell RNA Sequencing Profiling of Very Early-Stage Systemic Sclerosis Skin Reveals a Fibroblast Pro-inflammatory Gene Signature and Keratinocyte Dysregulation
Lumeng Li¹, Elena Pachera², Rucsandra Dobrota³, Kristina Bürki¹, Carina Mihai³, Muriel Elhai⁴, Laura Much¹, Astrid Hofman¹, Pietro Bearzi⁵, Sophie Wagner⁶, Sarah Lötscher⁷, Anna-Maria Hoffmann-Vold⁸ and Oliver Distler⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University Hospital zurich, Zürich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁶University of Zurich, Schlieren, Switzerland, ⁷Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Zurich, Switzerland, ⁸Oslo University Hospital, Oslo, Norway, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: The poor prognosis of patients with systemic sclerosis (SSc) underscores the need to prevent disease onset and irreversible organ damage. This study aims to…
Abstract Number: 2042 • ACR Convergence 2024
Overview of Lung Manifestations in Sarcoidosis and Various Treatment Approaches at a University Center
Aleeza Qamar¹, Upasana Agrawal², Karan Sachdeva³, Zara Hassan⁴, Alex Zamora¹, Syeda Nida⁵, Sarwat Umer¹, Samina Hayat¹ and Kinza Muzaffar⁶, ¹LSU Health-Shreveport, Shreveport, ²LSU Health, Shreveport, Shreveport, LA, ³Louisiana state university health shreveport LA, Shreveport, ⁴Louisiana State University Health Sciences, Shreveport, LA, ⁵LSU Healh-Shreveport, Shreveport, ⁶LSU HEALTH SHREVEPORT, SHREVEPORT, LA
Background/Purpose: Sarcoidosis is a disease occurring in the form of non-caseating granulomas, with unclear etiology and multi-system manifestations. Pulmonary involvement in sarcoidosis is a cardinal…
Abstract Number: 2562 • ACR Convergence 2024
Efficacy and Safety of Tocilizumab in the Treatment of Chronic Inflammatory Forms of CPPD: Retrospective Study of 55 Cases
Sophie Carrabin¹, Margaux Houze², Charlotte Jauffret³, Thomas Bardin⁴, Hang Korng Ea⁴, Frédéric Lioté⁴, Pascal Richette⁵, Tristan Pascart² and Augustin Latourte⁶, ¹Hôpital Lariboisière APHP.Nord, Paris, Paris, France, ²Lille Catholic University, Lille, France, ³Lille Catholic University, Lille, Nord-Pas-de-Calais, France, ⁴Hôpital Lariboisière APHP.Nord, Paris, France, ⁵Lariboisière Hospital, Paris, France, ⁶AP-HP, Paris, France
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a heterogeneous disease that can manifest as acute or chronic arthritis. Treatment options for chronic forms of the…
Abstract Number: 0024 • ACR Convergence 2024
Trans-Signaling by Soluble CD14 Sensitizes Chondrocytes to Lipopolysaccharide Stimuli, Increasing Chondrocyte Inflammatory Responses
Anna E. Rapp, Baofeng Hu and Carla Scanzello, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The understanding of osteoarthritis (OA) has evolved significantly over the past decade. Recently attention is being drawn to the role of pattern-recognition receptor (PRR)…
Abstract Number: 0246 • ACR Convergence 2024
Selectively Targeting TRBV11-2+ T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Using Bispecific T Cell-Engaging Antibodies
Elana Shaw, Stephanie Glavaris, Brian Mog, Alexander Pearlman, Sarah DiNapoli, Jin Liu, Kyle J. Kaeo, Kenneth W. Kinzler, Chetan Bettegowda, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but potentially deadly immune complication after infection with SARS-CoV-2. In patients with MIS-C, a striking…
Abstract Number: 0563 • ACR Convergence 2024
Clinical Features of Patients with SpA, with or Without IBD: Results from the METEOR Cohort
Manouk de hOoge¹, Pedro M. Machado², Sytske Anne Bergstra³, Maxime Dougados⁴, Clementina López Medina⁵, Victoria Navarro Compán⁶, Diego Benavent⁷, Denis Poddubnyy⁸, Levent kilic⁹, Philippe Carron¹⁰, Dirk Elewaut¹¹, Filip Van den Bosch¹² and Gaelle Varkas¹², ¹Dept. of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, ²Department of Rheumatology, University College London Hospitals NHS Foundation Trust; and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust; and Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³LUMC, Leiden, Netherlands, ⁴Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁵Reina Sofia University Hospital, Cordoba, Spain, ⁶La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ⁷Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, ⁸Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁹Dept. of Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, ¹⁰UZ Gent, Gent, Belgium, ¹¹Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ¹²Ghent University Hospital, Ghent, Belgium
Background/Purpose: To investigate clinical features of SpA patients with and without IBD, identifying the patient group that would benefit from initiating therapy with efficacy in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].